Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.

12-month DFS was 14.3% if MRD-positive vs 89.3% if MRD-negative. MRD positivity was associated with worse DFS in both arms (durvalumab HR 21.28, 95% CI 7.70-58.83; placebo HR 14.29, 95% CI 4.94-41.36). No MRD-positive patient in the durvalumab arm had a pathologic complete or major pathologic response. DFS trends favored durvalumab especially among MRD-negative patients (HR 0.56, 95% CI 0.26-1.20). KEAP1 and KMT2C mutations were associated with MRD-positive status in the durvalumab arm in this small exploratory analysis.

ASCO Annual Meeting 2025